NCT00529750View on ClinicalTrials.gov

Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

PHASE4CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Hypertension

Interventions

DRUG

IRBESARTAN

Tablets

DRUG

Atenolol

Tablets

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00529750 - Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension | Biotech Hunter | Biotech Hunter